Date: 2016-11-08
Type of information: Nomination
Compound:
Company: Neurovive Pharmaceutical (Sweden)
Therapeutic area: Rare diseases - Genetic diseases - Neurological diseases - Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On November 8, 2016, NeuroVive Pharmaceutical announced that the company has recruited Michele Tavecchio, PhD, as senior scientist. In his new role, Dr. Tavecchio will be leading R&D activities related to NeuroVive's discovery programs, working closely with CSO Eskil Elmér, CMO Magnus Hansson, and the core research team of scientists at NeuroVive. Dr. Tavecchio holds a PhD in Cancer Pharmacology from the Mario Negri Institute for Pharmacological Research in Milan and has authored over 20 scientific publications. Most recently he comes from a position as Associate Staff Scientist at Wistar Institute in Philadelphia, where his research activities have been focused on the involvement of ciclophilin D in various aspects of metabolic diseases and cancer.
Financial terms:
Latest news:
Is general: Yes
